← All trials
NCT02976805
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 13, 2017
- Primary completion
- Aug 1, 2019
- Completion date
- Dec 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 196
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Western OntarioLead sponsor
- University of AlbertaCollaborator
- McGill UniversityCollaborator
- University of Western OntarioOverall official - principal investigator
- PendopharmCollaborator
- Academic Medical Organization of Southwestern OntarioCollaborator
- University of MontrealCollaborator
- University of Western OntarioCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.